Immatics N.V. WarrantsIMTXW
About: Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
Employees: 423
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.36% less ownership
Funds ownership: 4.53% [Q4 2024] → 4.16% (-0.36%) [Q1 2025]
14% less funds holding
Funds holding: 14 [Q4 2024] → 12 (-2) [Q1 2025]
74% less capital invested
Capital invested by funds: $1.68M [Q4 2024] → $440K (-$1.24M) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for IMTXW.
Financial journalist opinion
We haven’t received any recent news articles for IMTXW.